10x Genomics' ATAC-Seq patents found valid and
infringed
PLEASANTON, Calif., March 3,
2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a
leader in single-cell and spatial biology, today provided an update
on its patent litigation with Parse Biosciences. Through a consent
agreement entered on February 25,
2025, in the United States
District Court for the District of Delaware, Parse agreed - a week before trial
was to start - to a worldwide permanent injunction that prevents it
from making, using, selling or offering for sale its planned ATAC
and ATAC-Multiome Single Cell products. As part of this consent
agreement, Parse admitted that 10x's ATAC-seq patents are valid,
enforceable and infringed by Parse's use of ATAC-seq methods and
compositions.
"This development further validates the strength of our broad
patent portfolio, which helps protect and preserve the world-class
innovation engine at 10x," said Eric S.
Whitaker, Chief Legal Officer of 10x Genomics. "We are
pleased with this resolution on ATAC as we continue to defend the
asserted Brenner patents on appeal."
The company's litigation against Parse's gene expression
products remains ongoing, with additional asserted patents under
appeal. Following entry of the injunction, the trial scheduled for
March 2025 concerning 10x's remaining
patent infringement claims against Parse has been stayed pending
those appeals.
10x Genomics is committed to defending its intellectual property
and investing in groundbreaking technologies that empower
researchers worldwide.
About 10x Genomics
10x Genomics is a life science technology company building
products to accelerate the mastery of biology and advance human
health. Our integrated solutions include instruments, consumables
and software for single cell and spatial biology, which help
academic and translational researchers and biopharmaceutical
companies understand biological systems at a resolution and scale
that matches the complexity of biology. Our products are behind
breakthroughs in oncology, immunology, neuroscience and more,
fueling powerful discoveries that are transforming the world's
understanding of health and disease. To learn more, visit
10xgenomics.com or connect with us on LinkedIn, X (Twitter),
Facebook, Bluesky or YouTube.
Forward Looking Statements
This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995 as contained in Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended, which fall under
the "safe harbor" provisions of those sections. All statements,
other than statements of historical facts, may be forward-looking
statements. Forward-looking statements generally can be identified
by the use of forward-looking terminology such as "may," "might,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "contemplate," "believe,"
"estimate," "predict," "potential" or "continue" or variations of
them or similar terminology, but the absence of these words does
not mean that a statement is not forward-looking. These
forward-looking statements include statements regarding litigation
and potential outcomes of litigation. These statements are based on
management's current expectations, forecasts, beliefs, assumptions
and information currently available to management, and actual
outcomes and results could differ materially from these statements
due to a number of factors. Other risks and uncertainties that
could affect 10x Genomics' financial and operating results and
cause actual results to differ materially from those indicated by
the forward-looking statements made in this press release include
those discussed under the captions "Risk Factors" and "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents 10x Genomics files with
the Securities and Exchange Commission (the "SEC") from time to
time. Although 10x Genomics believes that the expectations
reflected in the forward-looking statements are reasonable, it
cannot provide any assurance that these expectations will prove to
be correct nor can it guarantee that the future results, levels of
activity, performance and events and circumstances reflected in the
forward-looking statements will be achieved or occur. The
forward-looking statements in this press release are based on
information available to 10x Genomics as of the date hereof, and
10x Genomics disclaims any obligation to update any forward-looking
statements provided to reflect any change in its expectations or
any change in events, conditions or circumstances on which any such
statement is based, except as required by law. These
forward-looking statements should not be relied upon as
representing 10x Genomics' views as of any date subsequent to the
date of this press release.
Disclosure Information
10x Genomics uses filings with
the Securities and Exchange Commission, our website
(www.10xgenomics.com), press releases, public conference calls,
public webcasts and our social media accounts as means of
disclosing material non-public information and for complying with
our disclosure obligations under Regulation FD.
Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/10x-genomics-secures-injunction-against-parse-biosciences-planned-atac-products-302390537.html
SOURCE 10x Genomics, Inc
